1st May 2025 07:45
GSK PLC - London-based pharmaceutical maker - Says trial of Nucala, whose generic name is mepolizumab, shows positive results in the treatment of chronic obstructive pulmonary disease. The results shows a 21% reduction in the annualised rate of moderate-to-severe exacerbations in a wide COPD population. The study assesses mepolizumab, a monoclonal antibody that targets interleukin-5, in a variety of COPD patients. Nucala is not yet approved for the treatment of COPD in any country, but regulatory submissions are under review in several countries, GSK says, including the US, China and the EU. Read More
